External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology 2025 ASCO® Genitourinary Cancers Symposium
Roche and Genentech at

2025 ASCO® Genitourinary Cancers Symposium

February 13 - February 15
San Francisco, CA
conferences.asco.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Feb 14 / Roche and Genentech
Effectiveness and Safety of First-Line Atezolizumab in Locally Advanced or Metastatic Urothelial Cancer: The IMFLAME Study
The purpose of this analysis is to evaluate the real-word effectiveness and safety of atezolizumab monotherapy as first line treatment in locally advanced or mUC ineligible for platinum-based chemotherapies.
Oncology Urinary Bladder Cancer ASCO-GU-2025
07:30 PM
Duration 75mins San Francisco, CA
Effectiveness and Safety of First-Line Atezolizumab in Locally Advanced or Metastatic Urothelial Cancer: The IMFLAME Study
Alfonso Gómez de Liaño1, Nuria Romero-Laorden2, Pablo Gajate-Borau3, Alberto Orta-Ruiz4, Jesús García-Donas Jiménez5, Maria Jose Miranda Pallares6, Sergio Vázquez Estévez7, Carmen Molins8, Cristina Pernaut9, Marta González Cordero10, Ovidio Fernández11, José García Sánchez12, Iria González Maeso13, Patricia Rodríguez Blázquez14, Òscar Reig15, Pablo Maroto Rey16, Almudena Martín17, Ignacio Ramírez Gallegos18, Javier Puente19
Oncology | Urinary Bladder Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.